Ludvig André Munthe
- Professor; MD, PhD
- +47 2307 4371 / 9346 1540
Publications 2024
Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections
NPJ Vaccines, 9 (1), 185
DOI 10.1038/s41541-024-00972-3, PubMed 39384763
Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence
Front Immunol, 15, 1377041
DOI 10.3389/fimmu.2024.1377041, PubMed 38449865
People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination
Front Immunol, 14, 1235210
DOI 10.3389/fimmu.2023.1235210, PubMed 38299149
Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside
Front Immunol, 15, 1331345
DOI 10.3389/fimmu.2024.1331345, PubMed 38370401
CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity
Mol Ther Oncol, 32 (3), 200841
DOI 10.1016/j.omton.2024.200841, PubMed 39474602
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
Front Immunol, 15, 1296273
DOI 10.3389/fimmu.2024.1296273, PubMed 38455062
Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease
Clin Exp Immunol, 216 (1), 45-54
DOI 10.1093/cei/uxad135, PubMed 38133636
Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis
Eur J Haematol, 112 (5), 731-742
DOI 10.1111/ejh.14164, PubMed 38192186
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
EBioMedicine, 108, 105317
DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039
Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies
Harm Reduct J, 21 (1), 120
DOI 10.1186/s12954-024-01023-9, PubMed 38890611
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
RMD Open, 10 (2)
DOI 10.1136/rmdopen-2023-003545, PubMed 38599653
Publications 2023
Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence
Front Immunol, 14, 1265044
DOI 10.3389/fimmu.2023.1265044, PubMed 38045681
Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study
Front Immunol, 14, 1210899
DOI 10.3389/fimmu.2023.1210899, PubMed 37503339
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Cell Death Discov, 9 (1), 125
DOI 10.1038/s41420-023-01426-w, PubMed 37055391
Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study
EClinicalMedicine, 60, 102035
DOI 10.1016/j.eclinm.2023.102035, PubMed 37362086
Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
EBioMedicine, 97, 104833
DOI 10.1016/j.ebiom.2023.104833, PubMed 37844534
Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study
Lancet Healthy Longev, 4 (5), e188-e199
DOI 10.1016/S2666-7568(23)00055-7, PubMed 37148891
Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
NPJ Vaccines, 8 (1), 4
DOI 10.1038/s41541-023-00600-6, PubMed 36697432
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
JCI Insight, 8 (12)
DOI 10.1172/jci.insight.165111, PubMed 37159281
Publications 2022
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Lancet Rheumatol, 5 (1), e36-e46
DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
BMC Med, 20 (1), 378
DOI 10.1186/s12916-022-02587-8, PubMed 36199139
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
Mol Oncol, 16 (6), 1241-1258
DOI 10.1002/1878-0261.13191, PubMed 35148457
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
DOI 10.4049/jimmunol.2200144, PubMed 36426942
T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation
Br J Haematol, 198 (3), 556-573
DOI 10.1111/bjh.18285, PubMed 35655388
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
Nat Commun, 13 (1), 4165
DOI 10.1038/s41467-022-31888-y, PubMed 35851055
Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response
Am J Transplant, 22 (11), 2704-2706
DOI 10.1111/ajt.17091, PubMed 35533010
B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
Explor Target Antitumor Ther, 3 (1), 37-49
DOI 10.37349/etat.2022.00070, PubMed 35309250
A national intercalated medical student research program - student perceptions, satisfaction, and factors associated with pursuing a PhD
Med Educ Online, 27 (1), 2122105
DOI 10.1080/10872981.2022.2122105, PubMed 36069755
Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
Haematologica, 107 (8), 1994-1998
DOI 10.3324/haematol.2021.280393, PubMed 35236056
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002417, PubMed 36328399
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
NPJ Vaccines, 7 (1), 174
DOI 10.1038/s41541-022-00586-7, PubMed 36585405
Publications 2021
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
Eur Heart J, 42 (39), 4064-4072
DOI 10.1093/eurheartj/ehab506, PubMed 34405870
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Lancet Rheumatol, 4 (3), e177-e187
DOI 10.1016/S2665-9913(21)00394-5, PubMed 34977602
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
J Neurol Neurosurg Psychiatry, 94 (1), 19-22
DOI 10.1136/jnnp-2021-327612, PubMed 34670844
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
N Engl J Med, 384 (22), 2124-2130
DOI 10.1056/NEJMoa2104882, PubMed 33835768
Integration of T helper and BCR signals governs enhanced plasma cell differentiation of memory B cells by regulation of CD45 phosphatase activity
Cell Rep, 36 (6), 109525
DOI 10.1016/j.celrep.2021.109525, PubMed 34380042
Publications 2020
[Coronavirus – cross-immunity, herd immunity and vaccine development]
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0298, PubMed 32378847
The coronavirus - cross immunity, herd immunity and vaccine development
Tidsskr. Nor. Laegeforen., 140 (7), 650-652
Publications 2019
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
J Immunol, 202 (5), 1397-1405
DOI 10.4049/jimmunol.1701703, PubMed 30692213
B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells
Proc Natl Acad Sci U S A, 116 (51), 25850-25859
DOI 10.1073/pnas.1902836116, PubMed 31796587
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
Leukemia, 34 (2), 478-487
DOI 10.1038/s41375-019-0569-7, PubMed 31471562
Publications 2018
Cryopreservation of primary B cells minimally influences their signaling responses
Sci Rep, 8 (1), 17651
DOI 10.1038/s41598-018-36121-9, PubMed 30518828
Springboard to an academic career-A national medical student research program
PLoS One, 13 (4), e0195527
DOI 10.1371/journal.pone.0195527, PubMed 29708980
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia
Oncotarget, 9 (10), 9273-9284
DOI 10.18632/oncotarget.23949, PubMed 29507689
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303
Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients
Oncogene, 38 (13), 2420-2431
DOI 10.1038/s41388-018-0594-4, PubMed 30532071
Publications 2017
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
Leukemia, 31 (10), 2114-2121
DOI 10.1038/leu.2017.69, PubMed 28232741
Publications 2016
T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity
J Allergy Clin Immunol, 138 (3), 839-851.e8
DOI 10.1016/j.jaci.2016.01.035, PubMed 27056269
Publications 2015
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells
Haematologica, 101 (2), e59-62
DOI 10.3324/haematol.2015.135590, PubMed 26589914
Systemic Lupus Erythematosus: Molecular Mimicry between Anti-dsDNA CDR3 Idiotype, Microbial and Self Peptides-As Antigens for Th Cells
Front Immunol, 6, 382
DOI 10.3389/fimmu.2015.00382, PubMed 26284067
Publications 2014
Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism
J Immunol, 194 (2), 827-35
DOI 10.4049/jimmunol.1401350, PubMed 25505279
Association of variable number of tandem repeats in the coding region of the FAM46A gene, FAM46A rs11040 SNP and BAG6 rs3117582 SNP with susceptibility to tuberculosis
PLoS One, 9 (3), e91385
DOI 10.1371/journal.pone.0091385, PubMed 24625963
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871
Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells
J Immunol, 192 (9), 4174-83
DOI 10.4049/jimmunol.1302359, PubMed 24706724
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice
J Transl Med, 12, 207
DOI 10.1186/1479-5876-12-207, PubMed 25059102
Idiotype-specific Th cells support oligoclonal expansion of anti-dsDNA B cells in mice with lupus
J Immunol, 193 (6), 2691-8
DOI 10.4049/jimmunol.1400640, PubMed 25127856
Publications 2013
Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells
Cell Rep, 4 (3), 566-77
DOI 10.1016/j.celrep.2013.07.011, PubMed 23933259
Publications 2012
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases
Clin Dev Immunol, 2012, 957151
DOI 10.1155/2012/957151, PubMed 22474487
Publications 2011
NF-κB activity in perinatal brain during infectious and hypoxic-ischemic insults revealed by a reporter mouse
Brain Pathol, 22 (4), 499-510
DOI 10.1111/j.1750-3639.2011.00548.x, PubMed 22059637
B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives
Autoimmun Rev, 11 (1), 28-34
DOI 10.1016/j.autrev.2011.06.010, PubMed 21777703
A mild form of Mucopolysaccharidosis IIIB diagnosed with targeted next-generation sequencing of linked genomic regions
Eur J Hum Genet, 20 (1), 58-63
DOI 10.1038/ejhg.2011.126, PubMed 21712855
Publications 2010
The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation
Immunol Cell Biol, 88 (5), 515-22
DOI 10.1038/icb.2009.118, PubMed 20066000
Publications 2009
The idiotype connection: linking infection and multiple sclerosis
Trends Immunol, 31 (2), 56-62
DOI 10.1016/j.it.2009.11.001, PubMed 19962346
Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems
Am J Pathol, 174 (4), 1358-67
DOI 10.2353/ajpath.2009.080700, PubMed 19286564
Publications 2008
Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA)
Cell Signal, 21 (2), 274-81
DOI 10.1016/j.cellsig.2008.10.013, PubMed 19000925
Publications 2007
Immunologi
Universitetsforl., Oslo (2. utg.), 334 s.
BIBSYS 070820953, ISBN 978-82-15-01093-9
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells
J Exp Med, 204 (5), 1181-91
DOI 10.1084/jem.20061220, PubMed 17485509
Publications 2006
[The cow, the boy and the lymph node--immunological principles for vaccines]
Tidsskr Nor Laegeforen, 126 (19), 2532-7
PubMed 17028635
Publications 2005
Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells
J Immunol, 175 (4), 2391-400
DOI 10.4049/jimmunol.175.4.2391, PubMed 16081810
Publications 2004
Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models
Cancer Immunol Immunother, 53 (9), 759-69
DOI 10.1007/s00262-004-0504-1, PubMed 15088126
MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production
J Immunol, 172 (12), 7476-84
DOI 10.4049/jimmunol.172.12.7476, PubMed 15187126
Publications 2003
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies
Blood, 102 (2), 605-12
DOI 10.1182/blood-2002-11-3381, PubMed 12649166
Publications 2000
Immunologi
Universitetsforl., [Oslo], 295 s.
BIBSYS 991347749, ISBN 82-518-3875-4
Deletion of idiotype (Id)-specific T cells in multiple myeloma
Acta Oncol, 39 (7), 783-8
DOI 10.1080/028418600750063505, PubMed 11145433
Presentation of idiotopes to idiotope-specific T cells: idiotope-dependent T-B co-operation
[L.A. Munthe], [Oslo], 1 b. (flere pag.)
BIBSYS 011448709, ISBN 82-7633-158-0
Publications 1999
Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells
Nat Biotechnol, 17 (7), 670-5
DOI 10.1038/10883, PubMed 10404160
Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo
Eur J Immunol, 29 (12), 4043-52
DOI 10.1002/(SICI)1521-4141(199912)29:12<4043::AID-IMMU4043>3.0.CO;2-E, PubMed 10602015
Publications 1998
Transient overexpression of CD4 enhances allelic exclusion of T-cell receptor (TCR) alpha chains and promotes positive selection of class II-restricted TCR-transgenic thymocytes
Mol Immunol, 35 (1), 23-38
DOI 10.1016/s0161-5890(98)00004-2, PubMed 9683261
Publications 1997
Ludvig Munthe 1841-1896, Gerhard Munthe 1849-1929: 10. mai - 8. juni 1997
Galleri K, Oslo, [29] s.
BIBSYS 971259577
Publications 1996
Dual T cell receptor T cells have a decreased sensitivity to physiological ligands due to reduced density of each T cell receptor
Eur J Immunol, 26 (12), 2876-84
DOI 10.1002/eji.1830261211, PubMed 8977280
T cells with two Tcrbeta chains and reactivity to both MHC/idiotypic peptide and superantigen
Cell Immunol, 170 (2), 283-90
DOI 10.1006/cimm.1996.0162, PubMed 8660828
Publications 1995
Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies
Eur J Immunol, 25 (11), 3079-86
DOI 10.1002/eji.1830251114, PubMed 7489746
Preferential positive selection of T lymphocytes which express two different TCR alpha chains, an endogenous and a transgenic
Scand J Immunol, 42 (6), 651-61
DOI 10.1111/j.1365-3083.1995.tb03708.x, PubMed 8552989